We report the toxicity of high-dose chemotherapy (HDC) based on etoposide, thiotepa and CY (ETC) in children with poor-prognosis Ewing's sarcoma family tumors (ESFTs). A total of 26 patients with high-risk ESFT (metastasis or axis localization or tumor volume 4200 ml or necrosis o95%) were reviewed. The conditioning was based on etoposide (600 mg/m 2 ), thiotepa (750 mg/m 2 ) and CY (120 mg/kg) followed by autologous BM or PBSC rescue. The conditioning regimen was well tolerated, without any toxic deaths. The median time from transplant to a neutrophil count of 40.5 Â 10 9 /l was 10 days (range 6-27) and 22.5 days (range 9-114) for a plt count of 450 Â 10 9 /l. Oral mucositis was recorded in 20 patients, grade 1/2 in 19 and grade 3 in the last patient. Diarrhea grade 1/2 was recorded in four patients and grade 1/2 liver toxicity in four patients. Sepsis was documented in four cases and skin toxicity in three. Lung and tubular toxicity, respectively, were reported in one patient each. We conclude that the ETC regimen presented a limited and manageable toxicity. Further studies would confirm the role of ETC in high-risk ESFT.
The term Ewing's sarcoma family tumor (ESFT) has been coined to identify a group of highly aggressive, small round-cell tumors of neuroectodermal origin that is characterized by a chromosomal translocation, in most cases a reciprocal translocation t(11;22) (q24;q12). ESFT accounts for 3% of all pediatric tumors and represents the second most frequent bone malignancy. [1] [2] [3] In the past decade, ESFT outcome was improved largely through a multidisciplinary strategy based on surgery, radiotherapy and intensified chemotherapy regimens, [4] [5] [6] whereas large studies have identified risk factors associated with the worse prognosis. [4] [5] [6] [7] [8] Since the late 1980s, high-dose chemotherapy (HDC), followed by stem-cell rescue, has been proposed to improve the outcome of patients with poor-prognosis ESFT. Although many studies have been published, the role of HDC in ESFT remains unclear. The patient populations enrolled in the published studies were heterogeneous and treated with different conditioning regimens, most of them based on melphalan and/or BU. [9] [10] [11] This paper reports our experience with HDC based on etoposide, thiotepa and CY (ETC) in poor-prognosis ESFT cases treated at Ospedale Pediatrico Bambino Gesu`over the past 10 years.
Patients and methods

Patients
From November 1998 to December 2007, 26 consecutive patients affected by high-risk ESFT were diagnosed at Ospedale Pediatrico Bambino Gesu`. All patients presented at least one of the following risk factors: metastatic disease, primary tumor localized in the axis, tumor volume 4200 ml or poor histological response (necrosis o95%) after induction chemotherapy. Histological necrosis after induction chemotherapy was assessed at the time of definitive surgery based on the Huvos grading system. 12 A total of 24 patients achieved at least a partial response at the local and metastatic sites after surgery and/or induction chemotherapy; only patients in partial response were treated with HDC based on ETC. Two metastatic patients rapidly progressed during induction and did not reach the myeloablative phase. This report, therefore, concerns 24 patients in partial response after the induction phase; nevertheless, we report the survival of the whole population according to an intention-to-treat analysis. Medical records were retrospectively reviewed and patient characteristics and treatment are summarized in Tables 1 and 2 . At the last follow-up, patients were evaluated for long-term toxicities. Informed consent was signed by parents or the guardian. The protocol was approved by the institutional review board.
Treatment plan
Treatment consisted of seven cycles of induction chemotherapy, local therapy (surgery with or without radiotherapy) and HDC with autologous SCT (HDC/ASCT). Induction chemotherapy was based on two ifosfamide/ carboplatin/etoposide courses and two CY/doxorubicin/ VCR, as previously reported, 13 and two CY/etoposide courses and a subsequent CY/doxorubicin/VCR course (see Figure 1 ). Surgery was considered at diagnosis and after the fourth course. In inoperable patients, surgery was reconsidered after HDC/ASCT. Radiotherapy was performed after HDC/ASCT.
Toxicity and response evaluation
Evaluation of primary tumor was performed using computed tomography scan or magnetic resonance imaging; the tumor size was measured in three dimensions. Disease extension was assessed using total body computed tomography scan and 99 Technetium scintigraphy. Metastatic assessment was completed by two trephine samples and at least two aspirates of BM for morphologic evaluation.
Tumor responses at primary and metastatic sites were evaluated after the second and fourth courses, and before HDC/ASCT, using the same imaging tools used at diagnosis. Responses were assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST).
Toxicity was evaluated according to the Common Toxicity Criteria (CTC) version 3 14 and Bearman's criteria. 15 Statistical methods OS was defined as the time interval between the date of diagnosis and the date of death from any cause or the date of the last follow-up. EFS was defined as the time interval between the date of diagnosis and the date of first relapse or the date of the last follow-up. The Kaplan-Meier method was used for estimating survival curves. 16 The logrank test was used to compare the Kaplan-Meier curves. Analysis was performed with the Stata 9.0 statistical software package (StatCorp LP, College Station, TX, USA).
Conditioning regimen
Results
All 24 patients who had reached the myeloablative phase after induction chemotherapy completed the conditioning regimen without protocol violations.
Surgery was performed at diagnosis in two patients, whereas 13 patients underwent surgical control after the fourth course. In five patients, surgery was performed after HDC/ASCT. In four patients, only biopsy was performed: in one case, the parents refused the surgical procedure (arm amputation); in two cases, the patients were in CR after induction chemotherapy and the last patient with surgery planned after HDC/ASCT was considered inoperable.
Before HDC/ASCT, 16 patients were in complete response, achieved in 14 patients with chemotherapy and surgery and in two patients with chemotherapy alone (complete response after four courses), whereas eight patients had a partial response.
Local disease control was achieved in four patients by radiotherapy alone, in 12 patients by radiotherapy and surgery and in eight patients by surgery alone (see Table 2 ). In all cases, radiotherapy was administered after HDC/ ASCT.
Radiotherapy was administered in 16 patients. Details of doses and fields are shown in Table 2 .
Survival
The median follow-up was 37 months (range 13-129 months). The 7-year OS and EFS were 59% (95% confidence interval (CI) 35-76) and 49% (95% CI 26-69), respectively, whereas the 7-year OS and EFS after HDC/ ASCT were 64% (95% CI 38-81) and 61% (95% CI 36-79), respectively (see Figures 2 and 3) .
Relapse occurred in nine (38%) patients: six of them had a metastatic spread at onset and three had a localized Toxicity of etoposide, thiotepa and CY in ESFT I Ilari et al disease; in these three localized patients, relapse occurred at the primary site. The median time to relapse from diagnosis was 24 months (range 4-56 months), whereas the median time to relapse from HDC/ASCT was 15 months (range 4-56 months). Out of 26 patients, nine (29%) died of the disease; seven of them had metastatic spread at onset and two a localized disease. The first localized relapsed patient had a pelvis involvement and the latter had a skull involvement; in both cases, definitive surgery was not performed. Out of seven metastatic relapsed patients, only one presented isolated lung metastasis, whereas the other six patients presented multiple site metastasis and two of them progressed during the induction phase.
Toxicity
The median interval between diagnosis and HDCT/SCT was 8.5 months (range 7-15.3 months).
The median time from transplant to a neutrophil count of 40.5 Â 10 9 /l was 10 days (range 6-27), whereas the median time from transplant to a plt count of 450 Â 10 9 /l was 22.5 days (range 9-114).
Extra-hematological toxicity was mainly gastrointestinal. Using the Bearman's criteria, grade 2 oral mucositis was recorded in 18 (75%) patients, whereas two patients presented grade 1 and grade 3 mucositis, respectively. Diarrhea was recorded in four patients, grade 1 in two patients and grade 2 in two others. Liver toxicity was reported in four patients: grade 2 in three patients and grade 1 in the latter one. Only one patient presented grade 1 lung toxicity according to the Bearman's criteria. A sepsis was documented in four patients. One patient presented a grade 1 tubular toxicity, based on the Common Toxicity Criteria version 3, whereas a grade 1/2 skin toxicity was reported in three patients. No toxic deaths were reported after HDC.
In all, 17 patients were evaluable for long-term toxicities at a median follow-up from diagnosis of 64 months (range 22-129). None of these patients presented liver, heart or renal toxicities. One patient with paravertebral tumor presented bladder dysfunction since diagnosis. One patient with lung metastasis presented a restrictive lung dysfunction. Growth failure was reported in one patient, whereas ovarian impairment was reported in 5 of 10 patients. Testicular function was not evaluated. None presented leukemia or a second tumor.
Discussion
In the past 30 years, the outcome of patients with ESFT has improved through a multidisciplinary approach. Active Toxicity of etoposide, thiotepa and CY in ESFT I Ilari et al agents and optimal schedules and combinations have been identified. At the same time, improved local control attributed to radiotherapy and more aggressive surgery have also contributed to improved outcome. An EFS of 70% was achieved for patients with localized disease, and OS reached 80%. [4] [5] [6] [7] [8] [17] [18] [19] [20] [21] The outcome of metastatic patients remains dismal, especially for patients with bone and BM involvement. [4] [5] [6] [9] [10] [11] Rodriguez Galindo et al. 23 suggested risk stratification, taking into account simple clinical features, such as age, stage, tumor volume, localization and histological response to chemotherapy, to modulate treatment intensification in different subgroups.
HDC, followed by stem-cell rescue, has been proposed to improve outcome in high-risk ESFT, [18] [19] [20] [21] but the effect on outcome is not clear: some studies suggest an improvement in outcome, 4, [24] [25] [26] [27] [28] [29] [30] whereas others do not. [31] [32] [33] [34] [35] Only a randomized trial can confirm this role; the issue is currently being addressed in the EURO-EWING 99 Protocol.
In our study, we have considered patients with metastatic disease, tumor volume 4200 ml, or axis location, or low tumor necrosis rate after induction chemotherapy as poorprognosis ESFT patients. In recent reports, published after planning of our study, metastatic disease, older age, large tumors, histological response and exclusively pelvic primary tumor were associated with a worse prognosis, but only stage, tumor size and histological response retained prognostic significance on multivariate analysis. 20, 21, 23, 36 The 7-year EFS of 61%, achieved with the ETC conditioning regimen, seems encouraging, especially considering the survival reported in studies with conventional chemotherapy [18] [19] [20] [21] in which the EFS was always o40%. Nevertheless, Paulussen et al. 22 recently reported a 5-year EFS of 55% in high-risk ESFT using an intensive induction chemotherapy (EVAIA regimen) without HDC/ASCT, confirming that the effect of HDC/ASCT remains controversial.
In our experience, HDC/ASCT was useful for performing definitive surgery: in three localized patients with axis localization, surgery was possible after HDC/ASCT achieving a complete removal in two cases and none of these patients relapsed.
The pattern of relapse was confirmed as being associated with the quality of local control. The three localized and relapsed patients presented an axis localization (one skull and two pelvises): in all of them, definitive surgery was not performed, whereas radiotherapy was administered. In our experience, the HDC/ASCT does not prevent relapse in patients without adequate surgical control. In metastatic patients, the HDC/ASCT is often performed before local control on bulky disease to control metastatic spread, whereas in localized 'inoperable' patients it could be useful for achieving definitive surgery.
Different conditioning regimens have been used in high-risk ESFT, 4, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] but the best regimen has not yet been identified. Ladenstein 25 reported a better outcome for patients with the BU-based regimen. The toxicity of this regimen is significant, with a 25% incidence of veno-occlusive disease and a 4% rate of toxicity-related deaths attributed to acute respiratory distress syndrome and multiorgan system failure. 29 Moreover, fatal radiation myelopathy after high-dose BU and melphalan was described because of a synergistic interaction between HDC and radiotherapy. In ESFT, the HDC regimen should be carefully considered, particularly when radiotherapy encompassing the spinal cord is an essential component of management. 37 Vepeside and CY are widely known to be effective in treating ESFT, and vepeside is currently used in conditioning regimens. 21, 22, 24 Thiotepa has proved to be an interesting drug for inclusion in consolidation strategies, [38] [39] [40] [41] and it has been used in high-risk ESFT. 21, 24 A dose-effect relationship has been shown in vitro in various childhood solid tumor cell lines and pharmacokinetic data on these drugs have been extensively studied. Thiotepa and its major metabolite, tepa, reach CFS concentrations that are roughly equivalent to simultaneous plasma concentrations. 42 The mild toxicity makes this drug a valid candidate, either in combination regimens or in sequential HDC with PBSC support strategies.
The role of HDC/ASCT in localized patients is widely discussed with regard to poor-prognostic factors as well. In localized patients with poor risk factors, HDC/ASCT with BU-based regimen is frequently proposed; our experience showed that the ETC conditioning regimen is a good alternative in ESFT with axial necrosis of o95% or volume of 4200 ml. We suggest taking into consideration a less toxic conditioning regimen, such as ETC.
The survival of metastatic patients is dismal with current strategies; in particular, BM and multiple bone metastases are incurable, even with HDC/ASCT. As suggested by some researchers, 43, 44 tandem transplantation with BU-based conditioning seems a promising option for these patients, to be confirmed in large series. Our limited data point out a possible role of thiotepa in tandem transplantation for very high-risk ESFT. As reported in the literature, thiotepa has been used in tandem transplantation in combination with melphalan in patients affected by Ewing's sarcoma 45 and with carboplatin in pediatric central nervous system tumors to avoid craniospinal radiotherapy. 46 The overall toxicities of the thiotepa-based regimen were manageable and no toxic deaths were observed.
In conclusion, our conditioning regimen was well tolerated, without any toxic death, but our study presents some limitations, because of the heterogeneity and the small number of patients; more patients need to be accrued to confirm the role of ETC in this subset of ESFT population.
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